Tessera Therapeutics Appoints Joseph

Tessera Therapeutics announced a leadership change on July 23, 2026. Tessera Therapeutics appointed Joseph Romanelli, most recently a Merck executive, as President and CEO, succeeding Michael Severino, as the company shifts from platform innovation toward a broad portfolio of Gene Writing medicines.

What changed

Joseph Romanelli was named President and Chief Executive Officer. Romanelli succeeds Michael Severino, who has led the company since June 2022 and is moving to a new role leading a commercial stage biotech company, according to Chairman Geoff von Maltzahn.

Leader: Joseph Romanelli
Role: President and Chief Executive Officer
Effective: Not specified in the announcement
Announcement date: July 23, 2026

Leadership background

Romanelli comes to Tessera from Merck, where he most recently served as President, Human Health International, and a member of Merck’s Executive Team. He was responsible for Merck’s more than $25 billion international human health business and led teams across 75 markets outside the United States. From 2016 through 2021 he led Merck’s China business, and over a nearly 30-year career at Merck he held strategic and operational positions of increasing responsibility, including leadership of the company’s investor relations function.

The mandate

Tessera said Romanelli will guide its shift from a focus on platform innovation and preclinical development toward a broad portfolio of Gene Writing medicines, advancing a broad pipeline through clinical development. He will also join Tessera’s board of directors and become a CEO-Partner at its founder, Flagship Pioneering.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Tessera Therapeutics